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PERSISTENCE AND COMPLIANCE OF DEFEROXAMINE VERSUS 
DEFERASIROX IN MEDICAID PATIENTS WITH SICKLE-CELL DISEASE 
(SCD)
Jordan LB1, Vekeman F2, Sengupta A3, Corral M4, Guo A5, Duh MS6
1Sickle Cell Disease Association of America, Inc., Baltimore, MD, USA, 2Analysis Group, Inc., 
Washington , DC, USA, 3Analysis Group, Inc., San Francisco, CA, USA, 4Novartis Oncology, 
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OBJECTIVES: This study compares the frequency of hospitalizations, persistence, and 
compliance of SCD patients treated with deferoxamine (DFO) versus deferasirox 
(Exjade®), two iron chelating therapies (ICTs). METHODS: Health care claims from 
Medicaid Florida (1998–2007), Missouri (1993–2008), and New Jersey (1996–2008) 
were analyzed. Patients with continuous enrollment for ≥6 months prior to ICT initia-
tion and ≥1 SCD diagnosis were included. Patients were divided into four cohorts: 
treated with DFO (any DFO group), treated with deferasirox (any deferasirox group), 
initiated on DFO and then switched to deferasirox (deferasirox switchers), and treated 
with deferasirox only (deferasirox only group). Frequency of hospitalization for crisis 
conditions related to SCD pre- and post-ICT treatment initiation was assessed. Per-
sistence was deﬁned as time to drug discontinuation with ≥1 Rx gap. Compliance was 
estimated using the medication possession ratio (MPR) based on the drug exposure. 
RESULTS: 217, 275, 105, and 166 patients were included in the any DFO, any 
deferasirox, deferasirox switchers, and deferasirox only groups, respectively. After 
ICT initiation, the any deferasirox and deferasirox only groups experienced a signiﬁ-
cant reduction in the per patient per month frequency of hospitalizations relative to 
pre-treatment (any deferasirox: from 0.09 to 0.06, P = .0105; deferasirox only: from 
0.11 to 0.07, P = .0188). The Kaplan-Meier rates of medication persistence after one 
year of ICT were signiﬁcantly greater for all three deferasirox cohorts compared to 
the DFO cohort (any DFO: 0.21, any deferasirox: 0.29, deferasirox switchers: 0.37, 
deferasirox only: 0.24). Deferasirox treated patients were also signiﬁcantly more 
compliant than the DFO cohort (MPR, any DFO: 0.64, any deferasirox: 0.78, defera-
sirox switchers: 0.75, deferasirox only: 0.80). CONCLUSIONS: Deferasirox patients 
were more compliant and persistent to their treatment than those treated with DFO. 
Frequency of hospitalizations for SCD-related crisis conditions was signiﬁcantly 
reduced in the observation period for the any deferasirox and deferasirox only groups.
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CORRELATES OF ADHERENCE TO IMMUNOSUPPRESSANT 
MEDICATIONS IN COMMUNITY DWELLING SOLID ORGAN 
TRANSPLANT RECIPIENTS
Sankaranarayanan J1, Collier DS1, Furasek AN1, Smith LM1, McCartan M2, Langnas AN1
1University of Nebraska Medical Center, Omaha, NE, USA, 2The Nebraska Medical Center, 
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OBJECTIVES: To address limited data in Midwest solid organ transplant recipient 
(SOTR) populations we determined the patient’s demographic and medical character-
istics associated with self-reported immunosuppressant (IST) adherence on a 4-item 
measure (ITAS). METHODS: Cross-sectional survey-data (patient: residence zip code, 
education, marital status, annual income, health-status, insurance coverage; condition: 
comorbidities; therapy: total number of medications other than IST; and ITAS) was 
received from >/= 19 year old adult SOTR of an academic transplant center located 
in mid west US. For this retrospective study, survey-data were merged with other 
patient (age, race, gender); condition (transplant-type, years since last transplant); 
IST-drug therapy-data from the center’s database. Multivariate stepwise logistic 
regression was used to identify signiﬁcant patient characteristics for the dependent 
variable of being “adherent” (ITAS score = 12) compared with being “nonadherent” 
(ITAS score <12). RESULTS: Respondents had either kidney (269 [48.5%]), liver 
(263[47.2%]), or other (23[4.5%]) transplant. Other respondent characteristics were: 
age (mean 56 years), male (55.5%), white (90.1%), married (69.9%), less than 
$55,000 annual income (57.3%), metro-resident (59%), Medicare-insurance (47.8%), 
excellent to good health status (77.5%), years since last transplant (mean 7.53 +/− SD 
5.87). The SOTRs were on different IST regimens (Tacrolimus based combination IST 
drugs, 39.2%, Tacrolimus, 22.3%, Cyclosporine, 20.7%, Cyclosporine combinations, 
9%, Other, 8.8%). More than half (320/557; 57.5%) of the SOTRs self-reported 
“adherence”. In a multivariate stepwise logistic regression model including all patient 
characteristics; age less than 65 years (p = 0.0002), living in non metro rural areas (p 
= 0.041), and greater than or equal to 6 co-morbidities (p = 0.0040) signiﬁcantly 
decreased the likelihood of adherence compared with nonadherence. In the same 
model, however, Tacrolimus based combination-IST rather than Tacrolimus alone (p 
= 0.019), signiﬁcantly increased the likelihood of adherence compared with non-
adherence. CONCLUSIONS: Our study identiﬁed patient, condition, and IST-therapy 
correlates of IST-adherence which providers may consider to deliver IST-adherence 
improving interventions.
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COMPARING THE TIME TRADEOFF (TTO), THE VISUAL ANALOGUE 
SCALE (VAS) AND THE EQ-5D VALUE-SETS IN PATIENTS TREATED 
WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (PDPN) OR 
POST-HERPETIC NEURALGIA (PHN)
Gu NY1, Bell C2, Botteman M1, Van Hout BA3
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Park, NC, USA, 3University of Shefﬁeld, Shefﬁeld, UK
OBJECTIVES: To compare value sets derived from EQ-5D US tariffs and VAS and 
TTO in individuals with chronic pDPN/PHN. METHODS: This analysis was con-
ducted using baseline responses from 3 longitudinal surveys of adults with ≥3 months 
of pDPN/PHN who were receiving pain medications. Of them, 2719 completed the 
EQ-5D and VAS and, 2109 completed TTOs. Three value-sets were derived using: 
the EQ-5D classiﬁer (US-value-set), VAS, and TTO, which elicits patient willingness-
to-trade time for reduced pain. Generalized linear models were used to compare the 
covariate-adjusted values, adjusting for age, income, overall pain quality, and pain 
severity (PS) using numerical rating scale ranging from 0 (“no pain”) to 10 (“pain as 
bad as you can imagine”). Derived values were compared along PS, across all respon-
dents and by subgroups according to degrees of social/psychological difﬁculties due 
to pain. RESULTS: Mean respondent age was 55.48 (±10.65) years and 58.73% 
reported having a PS ≥ 6. Due to pain, 84% reported feeling older, 60.30% reported 
not feeling like going out and 60.29% wanted to be left alone. Mean values for 
EQ-5D, VAS and TTO were 0.594 (±0.215), 0.482 (±0.231) and −6.010 (±17.573), 
respectively. Mean covariate-adjusted values were 0.586 (±0.128), 0.471 (±0.075) and 
−6.156 (±4.151), respectively. All values decreased monotonically as PS increased. This 
monotonic relationship was strongest for TTO (resulting in a value of −11.98 at PS 
= 10 after covariate adjustment), followed by the EQ-5D, and VAS (p < 0.001). Similar 
results were found in stratiﬁed groups, especially in those with greater pDPN/PHN-
related social/psychological difﬁculties compared to other patients (p < 0.05). CON-
CLUSIONS: All three value-sets show scores signiﬁcantly related to PS. Findings 
suggest that value-sets with lower-end constrains (VAS, EQ-5D) are likely to under-
estimate the true value of preventing pain and may not lead to correct prioritization 
when considering health states that involve moderate to severe pain.
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HEALTH-RELATED FAMILY FUNCTIONING IN SYSTEMIC LUPUS 
ERYTHEMATOSUS (SLE)–PATIENT INTERVIEWS SUPPORT SIX 
DOMAINS
Hassette A1, Li T2, Savage S1, Radvanski D1, Buyske S3, Katz P4
1UMDNJ, New Brunswick, NJ, USA, 2Bristol-Myers Squibb Co., Princeton, NJ, USA, 3Rutgers 
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OBJECTIVES: The objective of this research was to identify domains of family social 
functioning that could be adversely impacted by SLE. METHODS: Twenty patients 
with SLE were interviewed on the impact of SLE in family functioning by telephone. 
Data were transcribed and descriptive statistics calculated. Domains were extracted 
using qualitative analysis evaluating relative support for the importance of each 
proposed domain. RESULTS: Participants were 18 females and 2 males (mean age = 
38). Most reported moderate to marked work disability, high-moderate social life 
disability and moderate disruption in family and home life. The meaning of “family” 
varied with 95% of patients listing immediate family members as their family, but 
70% included extended family. Six domains were identiﬁed: 1) Fatigue: When asked 
about the most bothersome symptom of SLE, fatigue was most frequently mentioned 
and reported as problematic by 90%; 2) Activities: 55% reported that ﬂares were 
unpredictable, but in contrast to what we anticipated, most patients learned how to 
cope with ﬂares. “active” activities (especially outdoor activities) were reportedly 
greatly affected by SLE; 3) Mental health: 88% reported that poor mental health 
impaired their ability to do the things that they liked to do with their families,;4) Isola-
tion: Withdrawal tended to occur during disease ﬂares. Such times were also often 
complicated by poor mood and extreme fatigue which contributed to the desire to be 
alone; 5) Of the 19 sexually active participants, 84% reported that SLE had a negative 
impact on their ability to have a gratifying sex life. Close to half reported that this 
distanced them from signiﬁcant others; and 6) Role Functioning: 80% described ways 
in which family roles were impacted, while 10% volunteered that SLE had signiﬁcantly 
impacted the family ﬁnancially. CONCLUSIONS: We found good support for 6 
domains related to family functioning in SLE and a questionnaire is being 
developed.
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WHAT ARE THE KEY ATTRIBUTES AND ENDPOINTS OF OVERWEIGHT 
AND OBESITY THERAPY? A CONCEPTUAL MAP OF PATIENT-CENTRED 
OUTCOMES
Mühlbacher AC1, Bethge S2
1University of Applied Sciences Neubrandenburg, Neubrandenburg, Germany, 2University of 
Applied Sciences Neubandenburg, Neubrandenburg, Germany
OBJECTIVES: Overweight and obesity impose a great burden on society. Though 
advances in obesity therapy can be observed, the long-lasting outcome is dissatisfying. 
This study aims at the identiﬁcation of patient-relevant attributes and endpoints in 
overweight and obesity therapy. Qualitative and quantitative methods were applied 
to identify a conceptual map of key attributes and endpoints. METHODS: Literature 
review (PubMed/Medline), focus groups (N = 44) and expert interviews (N = 5) were 
conducted to elicit patient preference over attributes and endpoints. A questionnaire 
with 124 possible attributes was conducted with N = 201 patients. Finally psycho-
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metric tests (frequency, factor analysis, reliability tests) were used to verify the rele-
vance and determinacy of the attributes. Repertory grid analysis was used to identify 
the constructs used by patients to characterize overweight and obesity therapy. 
Respondents were presented with cards outlining the preference dimensions and asked 
to rank the most relevant dimensions in order of relevance. RESULTS: The mapping 
of attributes and endpoints resulted in categories that emerged as relevant spanning 
from therapy attributes as technical care, access, empowerment and interpersonal care. 
The factor analysis of the attributes resulted in 8 factors with a KMO of 74.8; chron-
bachs alpha between 0.878 and 0.552 and a total mean square of 55.416%. The reper-
tory grid and ranking resulted in ﬁve patient-relevant endpoints (e.g. functional status, 
side effects, outcome and risk factors). CONCLUSIONS: The novelty of this analysis 
is the combination of qualitative and quantitative methods to build a conceptual map 
of patient-centered outcomes that can be used to plan comprehensive assessment of 
patient preferences in overweight and obesity therapy. The map concludes important 
attributes and endpoints and makes it possible to sort them in categories and subcat-
egories. Theoretical issues concerning the nature of attributes and their interrelation-
ships are raised and the implications for the measurement of patient preferences are 
discussed.
PSY40
EXTENDED-RELEASE OXYMORPHONE IS ASSOCIATED WITH LOWER 
SUBJECTIVE MONETARY VALUE THAN CONTROLLED-RELEASE 
OXYCODONE IN NONDEPENDENT RECREATIONAL OPIOID USERS
McMorn S, Hartry A, Thomson H, Berner T
Endo Pharmaceuticals, Chadds Ford, PA, USA
OBJECTIVES: This study assessed the subjective drug valuations of two opioids. This 
valuation may contribute to a better understanding of beneﬁciary preferences unre-
lated to drug effectiveness. METHODS: This exploratory, randomized, double-blind, 
placebo-controlled, 5-way crossover study compared the subjective and objective 
effects of equianalgesic doses of extended-release oxymorphone (15 mg and 30 mg) 
and controlled-release oxycodone (30 mg and 60 mg) plus placebo in healthy nonde-
pendent recreational opioid users. Subjects received single, double-blind, over- 
encapsulated, intact doses of each opioid or placebo treatment with ≥7 day washout 
period between treatments. Assessments included subjective drug value, a series of 
theoretical choices that forced subjects to select between receiving another dose of the 
same drug to take home or a speciﬁed amount of money in Canadian dollars ($). The 
Subjective Drug Value was administered at the 4, 8 and 24 hour time points of each 
treatment period with a minimum value of $0.25 and a maximum value of $48.00. 
RESULTS: Thirty ﬁve out of forty subjects completed the study. Extended-release 
oxymorphone was associated with statistically lower mean (SE) subjective drug values 
than equianalgesic doses of controlled-release oxycodone: extended-release oxymor-
phone 30 mg $16.85 (2.78) vs. controlled-release oxycodone 60 mg $24.32 (2.78), p 
= 0.013; extended-release oxymorphone 15 mg $9.85 (2.77) vs. controlled-release 
oxycodone 30 mg $25.00 (2.80), p < 0.001. CONCLUSIONS: Oral intact extended-
release oxymorphone had lower subjective drug values than equianalgesic doses of 
controlled-release oxycodone in this exploratory study. The impact of subjective valu-
ation on drug utilization patterns in recreational drug users and patients merits further 
investigation.
PSY41
PATIENT AND CAREGIVER-REPORTED SYMPTOMS AND REASONS FOR 
STARTING/STOPPING RECOMBINANT FACTOR VIIA (RFVIIA) 
TREATMENT: OBSERVATIONS FROM THE DOSING OBSERVATIONAL 
STUDY IN HEMOPHILIA (DOSE)
Valentino LA1, Walsh CE2, Reding M3, Tugal O4, Cooper DL5, Young G6
1RUSH University Medical Center, Chicago, IL, USA, 2Mount Sinai School of Medicine, New 
York, NY, USA, 3University of Minnesota Medical Center, Fairview, Minneapolis, MN, USA, 
4New York Medical College, Hawthorne, NY, USA, 5Novo Nordisk Inc., Princeton, NJ, USA, 
6Keck School of Medicine, USC, Los Angeles, CA, USA
OBJECTIVES: Treatment of acute bleeding episodes in patients with congenital 
hemophilia with inhibitors (CHwI) has transitioned largely to the home setting. The 
study aims to describe patient/caregiver perceptions of acute bleed symptoms, reasons 
for starting/stopping treatment, and choice of medication/dose. METHODS: 
Frequently-bleeding CHwI patients (≥4 bleeding episodes in 3 months) prescribed 
rFVIIa as ﬁrst-line therapy, or their caregivers, completed a daily diary for 3–6 months 
capturing bleeding symptoms and treatment decisions. RESULTS: Thirty-nine patients 
(median age 16.2) reported 194 hemorrhages (131 hemarthroses, 19 muscle, 44 
other). Pain was reported in 78.9% of bleeding episodes (90.1% joint, 89.5% muscle). 
Other recorded symptoms for bleeds (all/joint/muscle) included joint swelling 
(44.8%/65.6%/5.3%), decreased mobility/range of motion (41.2%/48.9%/68.4%), 
heat (21.1%/26.0%/15.8%), other swelling (16.0%/6.9%/47.4%), irritability 
(14.9%/16.8%/10.5%), bleeding (12.4%/7.6%/5.3%), and redness (10.3%/6.1%/ 
10.5%). A majority of patients/caregivers recognized when a bleed started 
(58.4%/58.0%), but were much less clear of when a bleed stopped (43.5%/33.3%). 
Medication was most commonly started by patients/caregivers when a bleed was 
identiﬁed (73.7%/47.4%) or because they were concerned a bleed might start and 
wanted to prevent it early (32.9%/27.6%). Common reasons for delays in starting 
medication by patients included ‘I thought it might not be a bleed’ (48.9%), ‘I wanted 
to see if the bleed progressed’ (46.8%), and ‘I thought it was just joint pain’ (44.7%). 
Most common reasons for caregivers were: ‘I wanted to see if it progressed’ (37.9%), 
‘I didn’t have medication’ (20.7%), and ‘I thought it might not be a bleed’ (17.2%). 
Reasons for stopping medication for patients/caregivers were pain cessation or stabi-
lization (93.9%/54.7%), arrest of swelling progression (60.6%/46.9%), and restora-
tion of mobility (50.0%/35.9%). CONCLUSIONS: Patients/caregivers have difﬁculty 
in determining bleed onset and particularly resolution, both quite necessary for clinical 
trials. Inability for caregivers to assess resolution in children may lead to longer treat-
ment duration seen in DOSE.
PSY42
ASSOCIATION BETWEEN SELF-REPORTED NEUROPATHIC PAIN 
SEVERITY AND THE EQ-5D IN PATIENTS WITH PAINFUL DIABETIC 
PERIPHERAL NEUROPATHY (PDPN) OR POST-HERPETIC NEURALGIA 
(PHN)
Gu NY1, Bell C2, Botteman M1, Van Hout BA3
1Pharmerit North America, LLC, Bethesda, MD, USA, 2GlaxoSmithBell, Research Triangle 
Park, NC, USA, 3University of Shefﬁeld, Shefﬁeld, UK
OBJECTIVES: To assess the association between self-reported neuropathic pain sever-
ity and the EQ-5D. METHODS: This study used data from baseline responses from 
2719 participants to 3 longitudinal internet surveys who: 1) reported ≥3 months of 
pDPN/PHN; 2) were receiving a prescription/OTC medication to treat pDPN/PHN; 
and 3) had completed a baseline EQ-5D. Ordered logistic regression models were used 
to assess the association between EQ-5D items and pain severity, adjusting for age, 
gender and years since pDPN/PHN diagnosis. Pain severity was assessed using the 
11-point pain-intensity numerical rating scale (0 = no pain to 10 = pain as bad as you 
can imagine). The likelihood-ratio test was used to test the proportionality of odds 
assumption. RESULTS: Respondents were 56% female, mean age 55.48 (±10.65) 
years, had pDPN/PHN duration for 5.1 (±4.7) years, and had mean (median) pain 
severity of 5.7 (6.0). The proportionality of odds assumption was not rejected (P < 
0.05). Compared with reference pain severity = 0, participants with greater pain sever-
ity were more likely to report greater health deﬁcits on the EQ-5D items. All covariates 
were signiﬁcantly (P ≤ 0.05) associated with the EQ-5D items except for age on 
“Mobility” and lower pain severity (1 or 2) on “Mobility” and “Self-care”. As 
expected, item “Pain/discomfort” demonstrated greater association with pDPN/PHN 
pain severity. For instance, relative to respondents with pain severity = 0, respondents 
with pain severity = 1 and = 10 were 2.52 (p = 0.026) and 1954.33 (p < 0.0001) times 
more likely to report more severe “pain/discomfort”, respectively. In comparison, 
respondents with pain severity = 10 were 13.05, 13.83, 24.50, and 38.83 times more 
likely to report more difﬁculties on “Self-care”, “Anxiety/depression” “Mobility”, and 
“Usual activities” (p < 0.0001), respectively, relative to respondents with pain severity 
= 0. CONCLUSIONS: A strong association exists between self-reported neuropathic 
pain severity and the EQ-5D. The EQ-5D is sensitive in detecting health disparities 
among moderate to severe chronic pDPN/PHN patients.
PSY43
A COMPARISON OF PHYSICIAN-PRESCRIBED AND PATIENT/
CAREGIVER REPORTED DOSING OF RECOMBINANT FACTOR VII 
(RFVIIA): HOME TREATMENT OF ACUTE BLEEDS IN THE DOSING 
OBSERVATIONAL STUDY IN HEMOPHILIA (DOSE)
Shapiro AD1, Cooper DL2, Carr Jr. ME2
1Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA, 2Novo Nordisk Inc., 
Princeton, NJ, USA
OBJECTIVES: Patients with congenital hemophilia with inhibitors (CHwI) experience 
acute bleeds that are managed with bypassing agents such as rFVIIa. Home treatment 
and dosing patterns in the US remain unknown. This study aimed to assess differences 
between prescribed/actual rFVIIa dosing in frequently-bleeding CHwI patients (≥4 
bleeds/3 months) prescribed ﬁrst-line therapy with rFVIIa. METHODS: Patients or 
caregivers recorded daily diaries including the details of all bypassing agent infusions 
on bleed/treatment days for 3–6 months. RESULTS: Median (range) initial rFVIIa 
dose prescribed by physicians for joint, muscle and other bleeds was 167.5 mcg/kg 
(61.0–289.0). Approximately 50% of initial rFVIIa doses prescribed were ≥160 mcg/
kg and 35% were ≥240 mcg/kg. Median prescribed additional rFVIIa dose for all 
bleeds was 90 mcg/kg (61.0–270.0) at an interval of 2.5–3 (1–24) hours. Median 
(range) actual initial rFVIIa dose reported by patients for 158 bleeds was 211.6 mcg/
kg (59.3–400.0), with total dose per episode of 694.9 mcg/kg (74.1–21,257.4). 
Patient/caregiver reported average dose per bleed was 146.1 mcg/kg (39.5–400) across 
5 (1.0–106.0) infusions. The initial rFVIIa dose was higher for joint bleeds (223.0 mcg/
kg [59.3–400.0]), compared with muscle (148.1 mcg/kg [74.1–300.0]; P = 0.07) and 
other bleeds (166.7 mcg/kg [64.0–400.0]; P = 0.02). Initial rFVIIa dose was ≥160 mcg/
kg in 65% of all bleeds and 73% of joint bleeds. The second dose for all bleeds was 
131.5 mcg/kg (29.6–379.7) with 43% being ≥160 mcg/kg and 27% ≥240 mcg/kg. 
CONCLUSIONS: Prescription data from the DOSE study demonstrate higher initial 
dosing for all bleed types than the package insert recommended dose of 90 mcg/kg. 
Additional prescribed dosing (where required) more closely conformed to package 
insert recommendations. Patient/caregiver reported actual dosing was generally higher 
than that prescribed, both for initial dosing (particularly for joint bleeds) and for 
additional dosing. These data suggest that patients/caregivers may have adopted home 
treatment strategies based upon individual responses and experience.
